Orhan Aktas

List of Articles by Year in descending order

Source: //exaly.com/author-pdf/3363252/publications.pdf

Version: 2025-02-01

248 peer-reviewed articles	16,909 peer-reviewed citations	17836 64 peer-reviewed h-index	538056 4.21 score
281 documents	19161 doc citations	20071 67 h-index	34003 citing authors

#	Article	IF	Citations
1	Expertenkonsensus: Meningokokkenprophylaxe in der Therapie neurologischer Erkrankungen mit Komplementinhibitoren. DGNeurologie, 2025, 8, 398-407.	0.3	4
2	Immune Checkpoint Inhibition–Related Myasthenia-Myositis-Myocarditis Responsive to Complement Blockade. Neurology: Neuroimmunology and NeuroInflammation, 2024, 11, .	3.7	37
3	Association of cytokine proteins with disease activity in NMOSD participants receiving inebilizumab treatment. Clinical Neurophysiology, 2024, 159, e19.	0.9	0
4	Matching-adjusted Indirect Comparison of Current Treatments for NMOSD and Evaluation of Long-term Effectiveness (P10-14.006). Neurology, 2024, 102, .	0.7	0
5	Association of Cytokine Proteins with Disease Activity in Neuromyelitis Optica Spectrum Disorder Participants Receiving Inebilizumab Treatment (S32.005). Neurology, 2024, 102, .	0.7	0
6	Individual Prognostication of Disease Activity and Disability Worsening in Multiple Sclerosis With Retinal Layer Thickness z Scores. Neurology: Neuroimmunology and NeuroInflammation, 2024, 11, .	3.7	13
7	Retinal Changes in Double-Antibody Seronegative Neuromyelitis Optica Spectrum Disorders. Neurology: Neuroimmunology and NeuroInflammation, 2024, 11, .	3.7	7
8	Heterophoria in multiple sclerosis patients: a proof of principle cross-sectional study. Frontiers in Immunology, 2024, 15, .	3.3	0
9	Eculizumab Use in Neuromyelitis Optica Spectrum Disorders. Neurology, 2024, 103, .	0.7	34
10	Cognitive Impairment, Associated Clinical Factors, and MR Volumetric Measures in Myelin Oligodendrocyte Glycoprotein-IgG–Associated Disease. Neurology: Neuroimmunology and NeuroInflammation, 2024, 11, .	3.7	11
11	Glial fibrillary acidic protein as a biomarker in neuromyelitis optica spectrum disorder: a current review. Expert Review of Clinical Immunology, 2023, 19, 71-91.	2.3	39
12	Myelinating Co-Culture as a Model to Study Anti-NMDAR Neurotoxicity. International Journal of Molecular Sciences, 2023, 24, 248.	3.2	3
13	Visually Evoked Potential as Prognostic Biomarker for Neuroaxonal Damage in Multiple Sclerosis From a Multicenter Longitudinal Cohort. Neurology: Neuroimmunology and NeuroInflammation, 2023, 10, .	3.7	25
14	Update on the diagnosis and treatment of neuromyelits optica spectrum disorders (NMOSD) – revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part I: Diagnosis and differential diagnosis. Journal of Neurology, 2023, 270, 3341-3368.	2.7	218
15	Effect of Previous Disease-Modifying Therapy on Treatment Effectiveness for Patients Treated With Ocrelizumab. Neurology: Neuroimmunology and NeuroInflammation, 2023, 10, .	3.7	11
16	Serum neurofilament light chain levels at attack predict post-attack disability worsening and are mitigated by inebilizumab: analysis of four potential biomarkers in neuromyelitis optica spectrum disorder. Journal of Neurology, Neurosurgery and Psychiatry, 2023, 94, 757-768.	4.2	46
17	Interferon beta-1a sc at 25 years: a mainstay in the treatment of multiple sclerosis over the period of one generation. Expert Review of Clinical Immunology, 2023, 19, 1343-1359.	2.3	14
18	Astrocytic outer retinal layer thinning is not a feature in AQP4-IgG seropositive neuromyelitis optica spectrum disorders. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, 188-195.	4.2	24

#	Article	IF	Citations
19	AQP4-IgG-seronegative patient outcomes in the N-MOmentum trial of inebilizumab in neuromyelitis optica spectrum disorder. Multiple Sclerosis and Related Disorders, 2022, 57, 103356.	1.4	38
20	CNS Involvement in Chronic Inflammatory Demyelinating Polyneuropathy. Neurology: Neuroimmunology and NeuroInflammation, 2022, 9, .	3.7	16
21	Glutaredoxin 2 promotes SP-1-dependent CSPG4 transcription and migration of wound healing NG2 glia and glioma cells: Enzymatic Taoism. Redox Biology, 2022, 49, 102221.	9.0	13
22	Disease-Modifying Drug Uptake and Health Service Use in the Ageing MS Population. Frontiers in Immunology, 2022, 12, .	3.3	11
23	Costs and Health-Related Quality of Life in Patients With NMO Spectrum Disorders and MOG-Antibody–Associated Disease. Neurology, 2022, 98, .	0.7	37
24	Cerebrospinal fluid findings in COVID-19: a multicenter study of 150 lumbar punctures in 127 patients. Journal of Neuroinflammation, 2022, 19, .	6.1	140
25	The degree of cortical plasticity correlates with cognitive performance in patients with Multiple Sclerosis. Brain Stimulation, 2022, 15, 403-413.	1.0	18
26	Interleukin-6 Receptor Blockade in Treatment-Refractory MOG-IgG–Associated Disease and Neuromyelitis Optica Spectrum Disorders. Neurology: Neuroimmunology and NeuroInflammation, 2022, 9, .	3.7	141
27	Immune response to SARS-CoV-2 vaccination in relation to peripheral immune cell profiles among patients with multiple sclerosis receiving ocrelizumab. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, 978-985.	4.2	29
28	Thinking outside the box: non-canonical targets in multiple sclerosis. Nature Reviews Drug Discovery, 2022, 21, 578-600.	43.4	113
29	Changing Perspectives from Oxidative Stress to Redox Signaling—Extracellular Redox Control in Translational Medicine. Antioxidants, 2022, 11, 1181.	4.6	33
30	Longitudinal Retinal Changes in MOGAD. Annals of Neurology, 2022, 92, 476-485.	4.6	57
31	Neuromyelitis-optica-Spektrum-Erkrankung: Pathogene Antikörper als Auslöser und Angriffspunkt. , 2022, , .		0
32	Worldwide Incidence and Prevalence of Neuromyelitis Optica. Neurology, 2021, 96, 59-77.	0.7	312
33	Anti-CD20 therapies and pregnancy in neuroimmunologic disorders. Neurology: Neuroimmunology and NeuroInflammation, 2021, 8, .	3.7	77
34	Long-term adherence and response to botulinum toxin in different indications. Annals of Clinical and Translational Neurology, 2021, 8, 15-28.	2.3	28
35	Pain, depression, and quality of life in adults with MOG-antibody–associated disease. European Journal of Neurology, 2021, 28, 1645-1658.	2.4	40
36	Sensitivity analysis of the primary endpoint from the N-MOmentum study of inebilizumab in NMOSD. Multiple Sclerosis Journal, 2021, 27, 2052-2061.	2.3	18

#	Article	IF	Citations
37	Epigallocatechin Gallate in Relapsing-Remitting Multiple Sclerosis. Neurology: Neuroimmunology and NeuroInflammation, 2021, 8, .	3.7	34
38	Disability Outcomes in the N-MOmentum Trial of Inebilizumab in Neuromyelitis Optica Spectrum Disorder. Neurology: Neuroimmunology and NeuroInflammation, 2021, 8, .	3.7	41
39	Von der Neuromyelitis optica zur Neuromyelitis-optica-Spektrum-Erkrankung: vom klinischen Syndrom zur Klassifikation. Der Nervenarzt, 2021, 92, 307-316.	0.5	3
40	Serum Glial Fibrillary Acidic Protein: A Neuromyelitis Optica Spectrum Disorder Biomarker. Annals of Neurology, 2021, 89, 895-910.	4.6	138
41	APOSTEL 2.0 Recommendations for Reporting Quantitative Optical Coherence Tomography Studies. Neurology, 2021, 97, 68-79.	0.7	228
42	Pain, Depression, and Quality of Life in Neuromyelitis Optica Spectrum Disorder. Neurology: Neuroimmunology and NeuroInflammation, 2021, 8, .	3.7	81
43	Artificial intelligence extension of the OSCAR-IB criteria. Annals of Clinical and Translational Neurology, 2021, 8, 1528-1542.	2.3	46
44	Association of Retinal Layer Thickness With Cognition in Patients With Multiple Sclerosis. Neurology: Neuroimmunology and NeuroInflammation, 2021, 8, .	3.7	23
45	Case Report: Successful Stabilization of Marburg Variant Multiple Sclerosis With Ocrelizumab Following High-Dose Cyclophosphamide Rescue. Frontiers in Neurology, 2021, 12, .	1.6	11
46	Ocrelizumab Extended Interval Dosing in Multiple Sclerosis in Times of COVID-19. Neurology: Neuroimmunology and NeuroInflammation, 2021, 8, .	3.7	107
47	Retinal Optical Coherence Tomography in Neuromyelitis Optica. Neurology: Neuroimmunology and NeuroInflammation, 2021, 8, .	3.7	86
48	Myelin-oligodendrocyte glycoprotein antibody-associated disease. Lancet Neurology, The, 2021, 20, 762-772.	13.7	504
49	C3 and C4 complement levels in AQP4-IgG-positive NMOSD and in MOGAD. Journal of Neuroimmunology, 2021, 360, 577699.	1.7	32
50	SPMS-Therapie bleibt eine Herausforderung. InFo Neurologie & Psychiatrie, 2021, 23, 19-19.	0.0	0
51	Targeting B Cells to Modify MS, NMOSD, and MOGAD. Neurology: Neuroimmunology and NeuroInflammation, 2021, 8, .	3.7	55
52	Targeting B cells to modify MS, NMOSD, and MOGAD. Neurology: Neuroimmunology and NeuroInflammation, 2021, 8, .	3.7	45
53	Relapse-independent multiple sclerosis progression under natalizumab. Brain Communications, 2021, 3, .	2.0	40
54	Case Report: Persisting Lymphopenia During Neuropsychiatric Tumefactive Multiple Sclerosis Rebound Upon Fingolimod Withdrawal. Frontiers in Neurology, 2021, 12, .	1.6	3

#	Article	IF	Citations
55	Safety and efficacy of erythropoietin for the treatment of patients with optic neuritis (TONE): a randomised, double-blind, multicentre, placebo-controlled study. Lancet Neurology, The, 2021, 20, 991-1000.	13.7	32
56	Retinal Structure and Function as a Predictor of Long-Term Visual Outcomes: A Post Hoc Analysis of RENEW and RENEWED (1945). Neurology, 2021, 96, .	0.7	1
57	Serum neurofilament light chain. Neurology: Neuroimmunology and NeuroInflammation, 2020, 7, .	3.7	44
58	Ocrelizumab Treatment in Patients with Primary Progressive Multiple Sclerosis: Short-term Safety Results from a Compassionate Use Programme in Germany. Clinical Neurology and Neurosurgery, 2020, 197, 106142.	1.0	9
59	Occipital repetitive transcranial magnetic stimulation does not affect multifocal visual evoked potentials. BMC Neuroscience, 2020, 21, .	1.5	2
60	Cerebrospinal fluid findings in patients with myelin oligodendrocyte glycoprotein (MOG) antibodies. Part 1: Results from 163 lumbar punctures in 100 adult patients. Journal of Neuroinflammation, 2020, 17, .	6.1	141
61	Cerebrospinal fluid findings in patients with myelin oligodendrocyte glycoprotein (MOG) antibodies. Part 2: Results from 108 lumbar punctures in 80 pediatric patients. Journal of Neuroinflammation, 2020, 17, .	6.1	71
62	Retinal layers and visual conductivity changes in a case series of microangiopathic ischemic stroke patients. BMC Neurology, 2020, 20, .	1.3	4
63	Case Report: A Case of Severe Clinical Deterioration in a Patient With Multiple Sclerosis. Frontiers in Neurology, 2020, 11, .	1.6	7
64	Cohort profile: a collaborative multicentre study of retinal optical coherence tomography in 539 patients with neuromyelitis optica spectrum disorders (CROCTINO). BMJ Open, 2020, 10, e035397.	1.2	19
65	Ocrelizumab zur Behandlung der Multiplen Sklerose. Der Nervenarzt, 2020, 91, 722-734.	0.5	3
66	Retinal Changes After Posterior Cerebral Artery Infarctions Display Different Patterns of the Nasal und Temporal Sector in a Case Series. Frontiers in Neurology, 2020, 11, .	1.6	6
67	Altered fovea in AQP4-IgG–seropositive neuromyelitis optica spectrum disorders. Neurology: Neuroimmunology and NeuroInflammation, 2020, 7, .	3.7	60
68	Capillary microscopy in Europeans with idiopathic Moyamoya angiopathy. Microcirculation, 2020, 27, .	1.3	1
69	Longitudinal optic neuritis-unrelated visual evoked potential changes in NMO spectrum disorders. Neurology, 2020, 94, .	0.7	47
70	The Rare IL22RA2 Signal Peptide Coding Variant rs28385692 Decreases Secretion of IL-22BP Isoform-1, -2 and -3 and Is Associated with Risk for Multiple Sclerosis. Cells, 2020, 9, 175.	3.3	4
71	Cryptococcal meningoencephalitis in an IgG2-deficient patient with multiple sclerosis on fingolimod therapy for more than five years – case report. BMC Neurology, 2020, 20, .	1.3	22
72	Protective effects of 4-aminopyridine in experimental optic neuritis and multiple sclerosis. Brain, 2020, 143, 1127-1142.	5.9	40

#	Article	IF	Citations
73	Clinicogenomic factors of biotherapy immunogenicity in autoimmune disease: A prospective multicohort study of the ABIRISK consortium. PLoS Medicine, 2020, 17, e1003348.	4.6	58
74	B-Zell-Depletion 2.0: Bei NMOSD ist Anti-CD19-Immuntherapie wirksam. InFo Neurologie & Psychiatrie, 2020, 22, 30-30.	0.0	0
75	Rituximab wirkt NMOSD-Schüben entgegen. InFo Neurologie & Psychiatrie, 2020, 22, 20-20.	0.0	0
76	Confirmed Progression independent of Relapse Activity in Multiple Sclerosis Patients under long-term Natalizumab Treatment. (1372). Neurology, 2020, 94, .	0.7	0
77	Extensive immune reconstitution inflammatory syndrome in Fingolimod-associated PML: a case report with 7 Tesla MRI data. BMC Neurology, 2019, 19, .	1.3	19
78	Drug Treatment of Clinically Isolated Syndrome. CNS Drugs, 2019, 33, 659-676.	3.8	19
79	No Alteration of Optical Coherence Tomography and Multifocal Visual Evoked Potentials in Eyes With Symptomatic Carotid Artery Disease. Frontiers in Neurology, 2019, 10, .	1.6	4
80	Factors associated with headache in intravenous immunoglobulin treatment for neurological diseases. Acta Neurologica Scandinavica, 2019, 140, 290-295.	0.6	7
81	Monitoring retinal changes with optical coherence tomography predicts neuronal loss in experimental autoimmune encephalomyelitis. Journal of Neuroinflammation, 2019, 16, .	6.1	42
82	Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial. Lancet, The, 2019, 394, 1352-1363.	46.9	708
83	Retinal inner nuclear layer volume reflects inflammatory disease activity in multiple sclerosis; a longitudinal OCT study. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2019, 5, .	0.4	51
84	Clinical presentation of Moyamoya angiopathy in Europeans: experiences from Germany with 200 patients. Journal of Neurology, 2019, 266, 1421-1428.	2.7	36
85	Regulation of sirtuin expression in autoimmune neuroinflammation: Induction of SIRT1 in oligodendrocyte progenitor cells. Neuroscience Letters, 2019, 704, 116-125.	1.3	28
86	Misdiagnoses and delay of diagnoses in Moyamoya angiopathy—a large Caucasian case series. Journal of Neurology, 2019, 266, 1153-1159.	2.7	37
87	Meningitis gone viral: description of the echovirus wave 2013 in Germany. BMC Infectious Diseases, 2019, 19, .	1.7	14
88	Assessing the anterior visual pathway in optic neuritis: recent experimental and clinical aspects. Current Opinion in Neurology, 2019, 32, 346-357.	2.4	9
89	Diagnosis of multiple sclerosis: revisions of the McDonald criteria 2017 – continuity and change. Current Opinion in Neurology, 2019, 32, 327-337.	2.4	50
90	Monoclonal Antibodies for Multiple Sclerosis: An Update. BioDrugs, 2019, 33, 61-78.	4.2	28

#	Article	IF	Citations
91	Managing Risks with Immune Therapies in Multiple Sclerosis. Drug Safety, 2019, 42, 633-647.	2.6	22
92	Detection and kinetics of persistent neutralizing anti-interferon-beta antibodies in patients with multiple sclerosis. Results from the ABIRISK prospective cohort study. Journal of Neuroimmunology, 2019, 326, 19-27.	1.7	24
93	High prevalence of neutralizing antibodies after long-term botulinum neurotoxin therapy. Neurology, 2019, 92, .	0.7	132
94	Therapie der multiplen Sklerose: Medikamentöse Ansätze zur Remyelinisierung in Prüfung. , 2019, , .		0
95	Factors associated with headache in intravenous immunoglobulin treatment for neurological diseases. (P5.2-071). Neurology, 2019, 92, .	0.7	0
96	Nimodipine confers clinical improvement in two models of experimental autoimmune encephalomyelitis. Journal of Neurochemistry, 2018, 146, 86-98.	2.7	33
97	Interferon β-1a and β-1b for patients with multiple sclerosis: updates to current knowledge. Expert Review of Clinical Immunology, 2018, 14, 137-153.	2.3	48
98	Early alpha-lipoic acid therapy protects from degeneration of the inner retinal layers and vision loss in an experimental autoimmune encephalomyelitis-optic neuritis model. Journal of Neuroinflammation, 2018, 15, .	6.1	46
99	Bewirkt das Antihistaminikum Clemastin eine Remyelinisierung?. InFo Neurologie & Psychiatrie, 2018, 20, 26-26.	0.0	0
100	Cladribin-Tabletten. Der Nervenarzt, 2018, 89, 895-907.	0.5	4
101	Shifting borders, crossing boundaries: The case of combined central and peripheral demyelination. Multiple Sclerosis Journal, 2018, 24, 550-551.	2.3	5
102	Multifocal visual evoked potentials in chronic inflammatory demyelinating polyneuropathy. Annals of Clinical and Translational Neurology, 2018, 5, 952-961.	2.3	7
103	Assessment of Opicinumab in Acute Optic Neuritis Using Multifocal Visual Evoked Potential. CNS Drugs, 2018, 32, 1159-1171.	3.8	47
104	Racial differences in neuromyelitis optica spectrum disorder. Neurology, 2018, 91, .	0.7	178
105	Apheresis therapies for NMOSD attacks. Neurology: Neuroimmunology and NeuroInflammation, 2018, 5, .	3.7	238
106	Acute sarcoidosis in a multiple sclerosis patient after alemtuzumab treatment. Multiple Sclerosis Journal, 2018, 24, 1776-1778.	2.3	20
107	Predictors of response to opicinumab in acute optic neuritis. Annals of Clinical and Translational Neurology, 2018, 5, 1154-1162.	2.3	24
108	Neuroimmunologische Register in Deutschland. Aktuelle Neurologie, 2018, 45, 7-23.	0.2	3

#	Article	IF	Citations
109	Diagnose der Multiplen Sklerose: Revision der McDonald-Kriterien 2017. Der Nervenarzt, 2018, 89, 1344-1354.	0.5	17
110	Alterations of the outer retina in non-arteritic anterior ischaemic optic neuropathy detected using spectral-domain optical coherence tomography. Clinical and Experimental Ophthalmology, 2017, 45, 496-508.	1.8	8
111	Safety and efficacy of opicinumab in acute optic neuritis (RENEW): a randomised, placebo-controlled, phase 2 trial. Lancet Neurology, The, 2017, 16, 189-199.	13.7	260
112	Immunotherapies in neuromyelitis optica spectrum disorder: efficacy and predictors of response. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, 639-647.	4.2	149
113	Iron-sulfur glutaredoxin 2 protects oligodendrocytes against damage induced by nitric oxide release from activated microglia. Glia, 2017, 65, 1521-1534.	3.6	46
114	Paraneoplastic limbic encephalitis with SOX1 and PCA2 antibodies and relapsing neurological symptoms in an adolescent with Hodgkin lymphoma. European Journal of Paediatric Neurology, 2017, 21, 661-665.	1.7	16
115	Retinal layer segmentation in multiple sclerosis: a systematic review and meta-analysis. Lancet Neurology, The, 2017, 16, 797-812.	13.7	585
116	Fulminant intramedullary spinal cord sarcoidosis. Multiple Sclerosis and Related Disorders, 2017, 18, 47-48.	1.4	2
117	Optical coherence tomography for the diagnosis and monitoring of idiopathic intracranial hypertension. Journal of Neurology, 2017, 264, 1370-1380.	2.7	65
118	Aquaporin-4 antibodies in patients treated with natalizumab for suspected MS. Neurology: Neuroimmunology and NeuroInflammation, 2017, 4, .	3.7	47
119	Influence of female sex and fertile age on neuromyelitis optica spectrum disorders. Multiple Sclerosis Journal, 2017, 23, 1092-1103.	2.3	80
120	Infectious risk stratification in multiple sclerosis patients receiving immunotherapy. Annals of Clinical and Translational Neurology, 2017, 4, 909-914.	2.3	17
121	Cellular composition of peripheral blood mononuclear cells during 4 years long-term treatment with fingolimod (P5.364). Neurology, 2017, 88, .	0.7	1
122	Optic neuritis as a phase 2 paradigm for neuroprotection therapies of multiple sclerosis. Current Opinion in Neurology, 2016, 29, 199-204.	2.4	45
123	Treatment of optic neuritis with erythropoietin (TONE): a randomised, double-blind, placebo-controlled trial—study protocol. BMJ Open, 2016, 6, e010956.	1.2	51
124	Multicentre comparison of a diagnostic assay: aquaporin-4 antibodies in neuromyelitis optica. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, 1005-1015.	4.2	297
125	Analysis of Plasminogen Genetic Variants in Multiple Sclerosis Patients. G3: Genes, Genomes, Genetics, 2016, 6, 2073-2079.	1.4	15
126	Activation of Wnt signaling promotes hippocampal neurogenesis in experimental autoimmune encephalomyelitis. Molecular Neurodegeneration, 2016, 11, .	9.9	26

#	Article	IF	Citations
127	MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 1: Frequency, syndrome specificity, influence of disease activity, long-term course, association with AQP4-IgG, and origin. Journal of Neuroinflammation, 2016, 13, .	6.1	403
128	MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: Epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome. Journal of Neuroinflammation, 2016, 13, .	6.1	832
129	MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 4: Afferent visual system damage after optic neuritis in MOG-IgG-seropositive versus AQP4-IgG-seropositive patients. Journal of Neuroinflammation, 2016, 13, .	6.1	249
130	Diagnostic criteria for Susac syndrome. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, 1287-1295.	4.2	227
131	MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 3: Brainstem involvement - frequency, presentation and outcome. Journal of Neuroinflammation, 2016, 13, .	6.1	234
132	Inositol 1,4,5-trisphosphate receptor type 1 autoantibodies in paraneoplastic and non-paraneoplastic peripheral neuropathy. Journal of Neuroinflammation, 2016, 13, .	6.1	26
133	Placebo-controlled study in neuromyelitis optica—Ethical and design considerations. Multiple Sclerosis Journal, 2016, 22, 862-872.	2.3	72
134	Dual roles of the adenosine A2a receptor in autoimmune neuroinflammation. Journal of Neuroinflammation, 2016, 13, .	6.1	88
135	Neuromyelitis optica: Evaluation of 871 attacks and 1,153 treatment courses. Annals of Neurology, 2016, 79, 206-216.	4.6	419
136	Retinal thickness measured with optical coherence tomography and risk of disability worsening in multiple sclerosis: a cohort study. Lancet Neurology, The, 2016, 15, 574-584.	13.7	327
137	Efficacy of glatiramer acetate in neuromyelitis optica spectrum disorder: a multicenter retrospective study. Journal of Neurology, 2016, 263, 575-582.	2.7	61
138	Serum peptide reactivities may distinguish neuromyelitis optica subgroups and multiple sclerosis. Neurology: Neuroimmunology and NeuroInflammation, 2016, 3, .	3.7	55
139	Evidence That the Anti-LINGO-1 Monoclonal Antibody BIIB033 Protects Against Multifocal Visual Evoked Potential Amplitude Loss in the Fellow Eye of Subjects with Unilateral Acute Optic Neuritis (I10.009). Neurology, 2016, 86, .	0.7	1
140	Evidence That the Anti-LINGO-1 Monoclonal Antibody BIIB033 Protects Against Multifocal Visual Evoked Potential Amplitude Loss in the Fellow Eye of Subjects with Unilateral Acute Optic Neuritis (S49.006). Neurology, 2016, 86, .	0.7	0
141	Natalizumab restores aberrant miRNAexpression profile in multiple sclerosis and reveals a critical role for miR-20b. Annals of Clinical and Translational Neurology, 2015, 2, 43-55.	2.3	76
142	Redox-regulated fate of neural stem progenitor cells. Biochimica Et Biophysica Acta - General Subjects, 2015, 1850, 1543-1554.	1.6	39
143	Long-term Therapy With Interleukin 6 Receptor Blockade in Highly Active Neuromyelitis Optica Spectrum Disorder. JAMA Neurology, 2015, 72, 756.	12.1	236
144	Use of Advanced Magnetic Resonance Imaging Techniques in Neuromyelitis Optica Spectrum Disorder. JAMA Neurology, 2015, 72, 815.	12.1	62

#	Article	IF	Citations
145	Acetazolamide therapy in a case of fingolimod-associated macular edema: early benefits and long-term limitations. Multiple Sclerosis and Related Disorders, 2015, 4, 406-408.	1.4	11
146	Pneumococcal meningitis and vaccine effects in the era of conjugate vaccination: results of 20 years of nationwide surveillance in Germany. BMC Infectious Diseases, 2015, 15, .	1.7	34
147	IFNβ secreted by microglia mediates clearance of myelin debris in CNS autoimmunity. Acta Neuropathologica Communications, 2015, 3, .	3.3	109
148	Genome-wide significant association with seven novel multiple sclerosis risk loci. Journal of Medical Genetics, 2015, 52, 848-855.	2.2	37
149	Gamma-aminobutyric acid receptor agonists, aquaporin-4, and neuromyelitis optica: a potential link. Medical Hypotheses, 2015, 85, 628-630.	0.5	6
150	Retinal pathology in idiopathic moyamoya angiopathy detected by optical coherence tomography. Neurology, 2015, 85, 521-527.	0.7	29
151	Retinal pathology in Susac syndrome detected by spectral-domain optical coherence tomography. Neurology, 2015, 85, 610-618.	0.7	61
152	Update on biomarkers in neuromyelitis optica. Neurology: Neuroimmunology and NeuroInflammation, 2015, 2, .	3.7	116
153	Alemtuzumab: A new therapy for active relapsing–remitting multiple sclerosis. Multiple Sclerosis Journal, 2015, 21, 22-34.	2.3	101
154	Advances in and Algorithms for the Treatment of Relapsing-Remitting Multiple Sclerosis. Neurotherapeutics, 2015, 13, 47-57.	3.9	41
155	BAX inhibitor-1 is a Ca2+ channel critically important for immune cell function and survival. Cell Death and Differentiation, 2015, 23, 358-368.	7.4	35
156	Safety and Tolerability of Anti-LINGO-1 Monoclonal Antibody BIIB033 in Acute Optic Neuritis: the RENEW trial (P7.203). Neurology, 2015, 84, .	0.7	0
157	Pregnancy does not prevent degeneration of retinal axons in multiple sclerosis (P5.206). Neurology, 2015, 84, .	0.7	0
158	Subtle retinal pathology in amyotrophic lateral sclerosis. Annals of Clinical and Translational Neurology, 2014, 1, 290-297.	2.3	75
159	Photoreceptor layer thinning in Parkinsonian syndromes. Movement Disorders, 2014, 29, 1222-1223.	3.2	14
160	Aquaporin-4 antibody testing: direct comparison of M1-AQP4-DNA-transfected cells with leaky scanning versus M23-AQP4-DNA-transfected cells as antigenic substrate. Journal of Neuroinflammation, 2014, 11, 129.	6.1	26
161	Interferon-β-related tumefactive brain lesion in a Caucasian patient with neuromyelitis optica and clinical stabilization with tocilizumab. BMC Neurology, 2014, 14, .	1.3	22
162	Biopsie bei tumorverdächtiger spinaler Raumforderung: Fallstrick Neuromyelitis optica. Der Nervenarzt, 2014, 85, 1298-1303.	0.5	2

#	Article	IF	Citations
163	Clinical, paraclinical and serological findings in Susac syndrome: an international multicenter study. Journal of Neuroinflammation, 2014, 11, 46.	6.1	119
164	Assessment of microRNA-related SNP effects in the 3' untranslated region of the IL22RA2 risk locus in multiple sclerosis. Neurogenetics, 2014, 15, 129-134.	0.9	19
165	Visual evoked potentials in neuromyelitis optica and its spectrum disorders. Multiple Sclerosis Journal, 2014, 20, 617-620.	2.3	56
166	MANBA, CXCR5, SOX8, RPS6KB1 and ZBTB46 are genetic risk loci for multiple sclerosis. Brain, 2013, 136, 1778-1782.	5.9	65
167	Disease Amelioration With Tocilizumab in a Treatment-Resistant Patient With Neuromyelitis Optica. JAMA Neurology, 2013, 70, 390.	12.1	116
168	Characteristics of Susac syndrome: a review of all reported cases. Nature Reviews Neurology, 2013, 9, 307-316.	18.3	349
169	Genome-wide significant association of ANKRD55 rs6859219 and multiple sclerosis risk. Journal of Medical Genetics, 2013, 50, 140-143.	2.2	35
170	Glutaredoxin regulates vascular development by reversible glutathionylation of sirtuin 1. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 20057-20062.	5.2	99
171	Retinal ganglion cell and inner plexiform layer thinning in clinically isolated syndrome. Multiple Sclerosis Journal, 2013, 19, 1887-1895.	2.3	145
172	Update on the diagnosis and treatment of neuromyelitis optica: Recommendations of the Neuromyelitis Optica Study Group (NEMOS). Journal of Neurology, 2013, 261, 1-16.	2.7	542
173	Optical Coherence Tomography in Parkinsonian Syndromes: The Impact of Different Techniques of Manual Segmentation (IN4-1.008). Neurology, 2013, 80, .	0.7	0
174	Optical Coherence Tomography in Parkinsonian Syndromes: The Impact of Different Techniques of Manual Segmentation (P06.079). Neurology, 2013, 80, .	0.7	0
175	Retinal Neurodegeneration in Wilson's Disease Revealed by Spectral Domain Optical Coherence Tomography (P06.008). Neurology, 2013, 80, .	0.7	0
176	Demyelination reduces brain parenchymal stiffness quantified in vivo by magnetic resonance elastography. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 6650-6655.	5.2	224
177	Degeneration of retinal layers in multiple sclerosis subtypes quantified by optical coherence tomography. Multiple Sclerosis Journal, 2012, 18, 1422-1429.	2.3	121
178	Failure of Natalizumab to Prevent Relapses in Neuromyelitis Optica. Archives of Neurology, 2012, 69, 239.	6.8	299
179	Closing the case of APOE in multiple sclerosis: no association with disease risk in over 29 000 subjects: Figure 1. Journal of Medical Genetics, 2012, 49, 558-562.	2.2	33
180	An emboligenic pulmonary abscess leading to ischemic stroke and secondary brain abscess. BMC Neurology, 2012, 12, .	1.3	9

#	Article	IF	Citations
181	p57kip2 regulates glial fate decision in adult neural stem cells. Development (Cambridge), 2012, 139, 3306-3315.	2.1	35
182	Testing for antibodies to human aquaporin-4 by ELISA: Sensitivity, specificity, and direct comparison with immunohistochemistry. Journal of the Neurological Sciences, 2012, 320, 32-37.	1.2	67
183	Optical Coherence Tomography in Parkinsonian Syndromes. PLoS ONE, 2012, 7, e34891.	1.5	166
184	Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: A multicentre study of 175 patients. Journal of Neuroinflammation, 2012, 9, .	6.1	711
185	Fingolimod in multiple sclerosis: Mechanisms of action and clinical efficacy. Clinical Immunology, 2012, 142, 15-24.	1.3	106
186	Cladribine as a therapeutic option in multiple sclerosis. Clinical Immunology, 2012, 142, 68-75.	1.3	13
187	Patterns of Retinal Damage Facilitate Differential Diagnosis between Susac Syndrome and MS. PLoS ONE, 2012, 7, e38741.	1.5	58
188	Retinal Neurodegeneration in Wilson's Disease Revealed by Spectral Domain Optical Coherence Tomography. PLoS ONE, 2012, 7, e49825.	1.5	50
189	Electrostatically stabilized magnetic nanoparticles – an optimized protocol to label murine T cells for in vivo MRI. Frontiers in Neurology, 2011, 2, .	1.6	15
190	The complex world of oligodendroglial differentiation inhibitors. Annals of Neurology, 2011, 69, 602-618.	4.6	124
191	Modulation of adult hippocampal neurogenesis during myelin-directed autoimmune neuroinflammation. Glia, 2011, 59, 132-142.	3.6	57
192	Therapie der Multiplen Sklerose mit monoklonalen Antikörpern: aktualisierte Empfehlungen zum Umgang mit Natalizumab im Rahmen eines Expertenmeetings. Aktuelle Neurologie, 2011, 38, 2-11.	0.2	5
193	Primary retinal pathology in multiple sclerosis as detected by optical coherence tomography. Brain, 2011, 134, e193-e193.	5.9	63
194	Alemtuzumab: eine weitere Chance zur Therapie der Multiplen Sklerose. Der Nervenarzt, 2011, 83, 487-501.	0.5	1
195	Independent replication of STAT3 association with multiple sclerosis risk in a large German case–control sample. Neurogenetics, 2011, 13, 83-86.	0.9	23
196	Neuroprotective Effect of Combination Therapy of Glatiramer Acetate and Epigallocatechin-3-Gallate in Neuroinflammation. PLoS ONE, 2011, 6, e25456.	1.5	89
197	Cladribin. Der Nervenarzt, 2010, 81, 194-202.	0.5	4
198	Oral therapies for multiple sclerosis: are we there yet?. Lancet Neurology, The, 2010, 9, 454-457.	13.7	7

#	Article	IF	Citations
199	Immunoproteasomes Preserve Protein Homeostasis upon Interferon-Induced Oxidative Stress. Cell, 2010, 142, 613-624.	23.4	550
200	Neuroprotection, regeneration and immunomodulation: broadening the therapeutic repertoire in multiple sclerosis. Trends in Neurosciences, 2010, 33, 140-152.	6.8	90
201	Fingolimod is a potential novel therapy for multiple sclerosis. Nature Reviews Neurology, 2010, 6, 373-382.	18.3	181
202	Neue therapeutische Konzepte bei der Multiplen Sklerose. Nervenheilkunde, 2010, 29, 267-272.	0.1	0
203	Cytotoxic CD8+T Cell–Neuron Interactions: Perforin-Dependent Electrical Silencing Precedes But Is Not Causally Linked to Neuronal Cell Death. Journal of Neuroscience, 2009, 29, 15397-15409.	2.3	89
204	Poor PASAT performance correlates with MRI contrast enhancement in multiple sclerosis. Neurology, 2009, 73, 1624-1627.	0.7	61
205	Lower motor neuron loss in multiple sclerosis and experimental autoimmune encephalomyelitis. Annals of Neurology, 2009, 66, 310-322.	4.6	162
206	Activation of kinin receptor B1 limits encephalitogenic T lymphocyte recruitment to the central nervous system. Nature Medicine, 2009, 15, 788-793.	22.6	128
207	MR spectroscopy (MRS) and magnetisation transfer imaging (MTI), lesion load and clinical scores in early relapsing remitting multiple sclerosis: a combined cross-sectional and longitudinal study. European Radiology, 2009, 19, 2066-2074.	3.0	35
208	Beyond blood brain barrier breakdown – in vivodetection of occult neuroinflammatory foci by magnetic nanoparticles in high field MRI. Journal of Neuroinflammation, 2009, 6, .	6.1	47
209	Development of oral cladribine for the treatment of multiple sclerosis. Journal of Neurology, 2009, 257, 163-170.	2.7	42
210	Sirt1 contributes critically to the redox-dependent fate of neural progenitors. Nature Cell Biology, 2008, 10, 385-394.	12.6	432
211	Roles of the kallikrein/kinin system in the adaptive immune system. International Immunopharmacology, 2008, 8, 155-160.	3.0	31
212	Autoregulation of Th1-mediated inflammation by twist1 . Journal of Experimental Medicine, 2008, 205, 1889-1901.	5.9	106
213	Neues zu Pathogenese, Diagnostik und Therapie der Neuromyelitis optica. Deutsche Medizinische Wochenschrift, 2008, 133, 1125-1129.	0.1	3
214	Oral High-Dose Atorvastatin Treatment in Relapsing-Remitting Multiple Sclerosis. PLoS ONE, 2008, 3, e1928.	1.5	114
215	Neuronal Damage in Brain Inflammation. Archives of Neurology, 2007, 64, 185.	6.8	234
216	Perioperative fluctuations of lamotrigine serum levels in patients undergoing epilepsy surgery. Seizure: the Journal of the British Epilepsy Association, 2007, 16, 479-484.	1.5	23

#	Article	IF	Citations
217	Impact of HMG-CoA reductase inhibition on brain pathology. Trends in Pharmacological Sciences, 2007, 28, 342-349.	8.2	59
218	The role of TRAIL/TRAIL receptors in central nervous system pathology. Frontiers in Bioscience - Landmark, 2007, 12, 2912.	5.8	64
219	Neurodegeneration in autoimmune demyelination: Recent mechanistic insights reveal novel therapeutic targets. Journal of Neuroimmunology, 2007, 184, 17-26.	1.7	43
220	TRAIL limits excessive host immune responses in bacterial meningitis. Journal of Clinical Investigation, 2007, 117, 2004-2013.	6.6	64
221	Antibody to Aquaporin 4 in the Diagnosis of Neuromyelitis Optica. PLoS Medicine, 2007, 4, e133.	4.6	192
222	The brain as a target of inflammation: common pathways link inflammatory and neurodegenerative diseases. Trends in Neurosciences, 2006, 29, 518-527.	6.8	342
223	Rezidivierendes reversibles posteriores Leukenzephalopathiesyndrom unter Chemotherapie mit Cisplatin und 5-Fluorouracil. Der Nervenarzt, 2006, 77, 706-710.	0.5	7
224	Death Ligands and Autoimmune Demyelination. Neuroscientist, 2006, 12, 305-316.	2.9	40
225	Tolerogenic effect of fiber tract injury: reduced EAE severity following entorhinal cortex lesion. Experimental Brain Research, 2006, 178, 542-553.	1.1	23
226	New aspects regarding mechanisms of tissue damage in the course of autoimmune demyelination. Signal Transduction, 2005, 5, 245-249.	0.5	0
227	Frequency of blood CX3CR1-positive natural killer cells correlates with disease activity in multiple sclerosis patients. FASEB Journal, 2005, 19, 1902-1904.	2.3	91
228	Indolamine 2,3-dioxygenase is expressed in the CNS and down-regulates autoimmune inflammation. FASEB Journal, 2005, 19, 1347-1349.	2.3	273
229	Neuronal Damage in Autoimmune Neuroinflammation Mediated by the Death Ligand TRAIL. Neuron, 2005, 46, 421-432.	8.2	220
230	Multiple Sklerose – weit mehr als eine Entmarkungskrankheit. E-Neuroforum, 2004, 10, 188-194.	0.2	0
231	Progressive change in primary progressive multiple sclerosis normal-appearing white matter: a serial diffusion magnetic resonance imaging study. Multiple Sclerosis Journal, 2004, 10, 182-187.	2.3	49
232	Direct Impact of T Cells on Neurons Revealed by Two-Photon Microscopy in Living Brain Tissue. Journal of Neuroscience, 2004, 24, 2458-2464.	2.3	136
233	Changes in cerebral perfusion precede plaque formation in multiple sclerosis: a longitudinal perfusion MRI study. Brain, 2004, 127, 111-119.	5.9	210
234	Green Tea Epigallocatechin-3-Gallate Mediates T Cellular NF-κB Inhibition and Exerts Neuroprotection in Autoimmune Encephalomyelitis. Journal of Immunology, 2004, 173, 5794-5800.	0.8	328

#	Article	IF	Citations
235	Identification and functional characterization of a highly polymorphic region in the human TRAIL promoter in multiple sclerosis. Journal of Neuroimmunology, 2004, 149, 195-201.	1.7	25
236	Systemic IFN-β treatment induces apoptosis of peripheral immune cells in MS patients. Journal of Neuroimmunology, 2003, 137, 187-196.	1.7	47
237	TNF-related apoptosis inducing ligand (TRAIL) as a potential response marker for interferon-beta treatment in multiple sclerosis. Lancet, The, 2003, 361, 2036-2043.	46.9	197
238	Treatment of Relapsing Paralysis in Experimental Encephalomyelitis by Targeting Th1 Cells through Atorvastatin. Journal of Experimental Medicine, 2003, 197, 725-733.	5.9	279
239	Activation of Microglial Poly(ADP-Ribose)-Polymerase-1 by Cholesterol Breakdown Products during Neuroinflammation. Journal of Experimental Medicine, 2003, 198, 1729-1740.	5.9	153
240	Elevated Bcl-XL levels correlate with T cell survival in multiple sclerosis. Journal of Neuroimmunology, 2002, 126, 213-220.	1.7	31
241	Polyspecific immunoglobulins (IVIg) suppress proliferation of human (auto)antigen-specific T cells without inducing apoptosis. Journal of Neuroimmunology, 2001, 114, 160-167.	1.7	42
242	Partial synergy of bisindolylmaleimide with apoptotic stimulus in antigen-specific T cells — implications for multiple sclerosis1This work was supported by grants from the DFG, the Hertie-Stiftung and the DMSG.1. Journal of Neuroimmunology, 2000, 103, 69-75.	1.7	5
243	Apoptose bei multipler Sklerose. Der Nervenarzt, 2000, 71, 767-773.	0.5	2
244	Remyelinisierungsförderung als zukünftiges Therapieprinzip der Multiplen Sklerose?. Der Nervenarzt, 1998, 69, 841-850.	0.5	0
245	Therapeutic approaches in adults with myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD): A review of current evidence. Autoimmunity Reviews, 0, 25, 103970.	5.3	2
246	Prescription Drug Use in NMOSD: A Population-Based Study in Greece with Estimation of National Disease Administrative Prevalence. Journal of Clinical Medicine, 0, 14, 8665.	1.8	0
247	OCT-Based Differentiation of First Acute Optic Neuritis. Neurology: Neuroimmunology and NeuroInflammation, 0, 13, .	3.7	5
248	Cognitive training, exercise training or combined training? A comparative effectiveness research study on subjective and objective cognitive outcomes in multiple sclerosis. Journal of Neurology, 0, 273, .	2.7	0